Artemisia extracts differ from artemisinin effects on human hepatic CYP450s 2B6 and 3A4 in vitro

Kane, Ndeye F.; Kiani, Bushra Hafeez; Desrosiers, Matthew R.; Towler, Melissa J.; Weathers, Pamela J.

doi:10.1016/j.jep.2022.115587

Cited by 10 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 Altogether, these observations suggest that some non-ART phytochemicals could either be active against the hepatic and transmittable Plasmodium stages, capable of improving the pharmacokinetics of ART and/or synergizing its action. 26,33,34,[42][43][44][45][46][47][48] The radical cure of P. vivax, mediated by hypnozoite elimination, together with the blockage of P. falciparum (especially ART-resistant) and P. vivax transmission, mediated by gametocyte sterilization, remain pivotal elements of malaria eradication. Current drug treatments targeting these stages are restricted to the 8-aminoquinolines primaquine and tafenoquine, [49][50][51] a paucity worsened by their double dependence on the host genetic to elicit clinical activity (CYP2D6-dependent) without severe toxicity (G6PD-dependent).…”

Section: Introductionmentioning

confidence: 99%

Future antimalarials fromArtemisia? A rationale for natural product mining against drug-refractoryPlasmodiumstages

2023

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Future antimalarials fromArtemisia? A rationale for natural product mining against drug-refractoryPlasmodiumstages

2023

View full text Add to dashboard Cite

show abstract

“…Cytochrome P450 (CYPs) is a superfamily of hemeprotein enzymes present in the livers of humans, whose function is to metabolize xenobiotics. These enzymes are involved in the first-pass effect of many drugs, including artemisinin, which is actively metabolized by CYP2B6 and CYP3A4 enzymes [ 52 ]. Medicinal plants and or pure molecules with safety profiles that can inhibit cytochrome P450 enzymes, especially CYP2B6 and CYP3A4, which are responsible for the metabolism of artemisinin, can be utilized as a traditional remedy or as modern therapy in combination with artemisinin, respectively, to fight malaria.…”

Section: Resultsmentioning

confidence: 99%

Secondary Metabolites Isolated from Artemisia afra and Artemisia annua and Their Anti-Malarial, Anti-Inflammatory and Immunomodulating Properties—Pharmacokinetics and Pharmacodynamics: A Review

et al. 2023

View full text Add to dashboard Cite

There are over 500 species of the genus Artemisia in the Asteraceae family distributed over the globe, with varying potentials to treat different ailments. Following the isolation of artemisinin (a potent anti-malarial compound with a sesquiterpene backbone) from Artemisia annua, the phytochemical composition of this species has been of interest over recent decades. Additionally, the number of phytochemical investigations of other species, including those of Artemisia afra in a search for new molecules with pharmacological potentials, has increased in recent years. This has led to the isolation of several compounds from both species, including a majority of monoterpenes, sesquiterpenes, and polyphenols with varying pharmacological activities. This review aims to discuss the most important compounds present in both plant species with anti-malarial properties, anti-inflammatory potentials, and immunomodulating properties, with an emphasis on their pharmacokinetics and pharmacodynamics properties. Additionally, the toxicity of both plants and their anti-malaria properties, including those of other species in the genus Artemisia, is discussed. As such, data were collected via a thorough literature search in web databases, such as ResearchGate, ScienceDirect, Google scholar, PubMed, Phytochemical and Ethnobotanical databases, up to 2022. A distinction was made between compounds involved in a direct anti-plasmodial activity and those expressing anti-inflammatory and immunomodulating activities or anti-fever properties. For pharmacokinetics activities, a distinction was made between compounds influencing bioavailability (CYP effect or P-Glycoprotein effect) and those affecting the stability of pharmacodynamic active components.

show abstract

“…Dried plant leaves were processed as previously described to produce DCM extracts [ 38 ]. DCM extracts were pooled and dried under N 2 as previously detailed [ 46 ], and ART was analyzed using GC-MS as described [ 47 ]. Hot water tea infusions were also prepared as detailed in Desrosiers et al [ 46 ].…”

Section: Methodsmentioning

confidence: 99%

Artemisia afra and Artemisia annua Extracts Have Bactericidal Activity against Mycobacterium tuberculosis in Physiologically Relevant Carbon Sources and Hypoxia

et al. 2023

Self Cite

View full text Add to dashboard Cite

Mycobacterium tuberculosis (Mtb) is a deadly pathogen and causative agent of human tuberculosis, causing ~1.5 million deaths every year. The increasing drug resistance of this pathogen necessitates novel and improved treatment strategies. A crucial aspect of the host–pathogen interaction is bacterial nutrition. In this study, Artemisia annua and Artemisia afra dichloromethane extracts were tested for bactericidal activity against Mtb strain mc26230 under hypoxia and various infection-associated carbon sources (glycerol, glucose, and cholesterol). Both extracts showed significant bactericidal activity against Mtb, regardless of carbon source. Based on killing curves, A. afra showed the most consistent bactericidal activity against Mtb for all tested carbon sources, whereas A. annua showed the highest bactericidal activity in 7H9 minimal media with glycerol. Both extracts retained their bactericidal activity against Mtb under hypoxic conditions. Further investigations are required to determine the mechanism of action of these extracts and identify their active constituent compounds.

show abstract

Artemisia extracts differ from artemisinin effects on human hepatic CYP450s 2B6 and 3A4 in vitro

Cited by 10 publications

References 38 publications

Future antimalarials fromArtemisia? A rationale for natural product mining against drug-refractoryPlasmodiumstages

Future antimalarials fromArtemisia? A rationale for natural product mining against drug-refractoryPlasmodiumstages

Secondary Metabolites Isolated from Artemisia afra and Artemisia annua and Their Anti-Malarial, Anti-Inflammatory and Immunomodulating Properties—Pharmacokinetics and Pharmacodynamics: A Review

Artemisia afra and Artemisia annua Extracts Have Bactericidal Activity against Mycobacterium tuberculosis in Physiologically Relevant Carbon Sources and Hypoxia

Contact Info

Product

Resources

About